Scientists Found a New Drug Which Treats Breast Cancer Like a Guided Missile

Scientists Found a New Drug Which Treats Breast Cancer Like a Guided Missile

The latest breakthrough in finding a cure for treating breast cancer can be a game-changer. Probably, in the current year, more than 265,000 people across the U.S. will be diagnosed with the disease. But there is always a ray of hope which might change the way to treat breast cancer. On Wednesday, doctors have reported incredibly good results from tests of two experimental medications. The drug has offered the best results in women having a severe type of breast cancer that had spread broadly in the body. Besides this, it has resulted best from a wide range of existing and former remedies.

One of the drugs under clinical trial has revealed specific power to reach tumors in the brain, which are particularly difficult to cure. Besides, the second drug couples a type of tracking device for cancer cells with a shipment of chemotherapy. Notably, the pill emits medicine when it reaches the target or cancer-affected cells. Dr. Ian Krop, from Boston’s Dana-Farber Cancer Institute, calls it a guided missile, which can introduce the medicine directly to the cancer cell. The trial focused on a cancer medication created by Daiichi Sankyo and AstraZeneca. The newly-developed cancer drug has kept back metastatic breast cancer for many months.

Dr. Krop has led the trial, which included more than 250 women having a severe form of breast cancer HER2-positive. Notably, the candidates had attempted using around six former medications before the new one. During the study, researchers have tested the drug in different doses. Among all women, up to 61% have experienced 30% shrinkage in the tumors.  Even more, in 6% of women, no symptoms of cancer were noticed up to two subsequent scans. Dr. Krop said they had not tested the medicine against other forms of cancer. Still, the response rate remains 3-4 times better than other patients. The researchers have presented their study in the New England Journal of Medicine and at the San Antonio Breast Cancer Symposium.

Related posts

Leave a Comment